Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	MiNK Therapeutics, Inc.	Common Stock [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member] MiNK Therapeutics, Inc.	Treasury Stock [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Non-controlling Interest [Member]	Non-controlling Interest [Member] MiNK Therapeutics, Inc.	Accumulated Deficit [Member]	Series A-1 convertible preferred stock [Member] Preferred Stock [Member]
Beginning balance at Dec. 31, 2023	$ (148,382)		$ 197	$ 1,796,095			$ (955)	$ 11,949		$ (1,955,668)	$ 0
Balance, shares at Dec. 31, 2023			19,718								32
Net loss	(63,454)							(1,568)		(61,886)
Other comprehensive income (loss)	(116)						(116)
Share-based compensation	4,196			3,477				719
Shares sold at the market	17,171		$ 13	17,158
Shares sold at the market, shares			1,249
Payment of CEO payroll in shares	89			89
Payment of CEO payroll In shares, shares			7
Vesting of nonvested shares, shares			8
Exercise of stock options and employee share purchases	173			166				7
Exercise of stock options and employee share purchases, shares			12
Ending balance at Mar. 31, 2024	(190,323)		$ 210	1,816,985			(1,071)	11,107		(2,017,554)	$ 0
Balance, shares at Mar. 31, 2024			20,994								32
Beginning balance at Dec. 31, 2023	(148,382)		$ 197	1,796,095			(955)	11,949		(1,955,668)	$ 0
Balance, shares at Dec. 31, 2023			19,718								32
Net loss	(118,251)
Other comprehensive income (loss)	(46)
Ending balance at Jun. 30, 2024	(220,839)		$ 211	1,830,114			(1,001)	20,472		(2,070,635)	$ 0
Balance, shares at Jun. 30, 2024			21,126								32
Beginning balance at Dec. 31, 2023	(148,382)		$ 197	1,796,095			(955)	11,949		(1,955,668)	$ 0
Balance, shares at Dec. 31, 2023			19,718								32
Share-based compensation								2,812
Ending balance at Dec. 31, 2024	(306,424)		$ 236	1,857,662			(1,398)	19,956		(2,182,880)	$ 0
Balance, shares at Dec. 31, 2024			23,635								32
Beginning balance at Mar. 31, 2024	(190,323)		$ 210	1,816,985			(1,071)	11,107		(2,017,554)	$ 0
Balance, shares at Mar. 31, 2024			20,994								32
Net loss	(54,797)							(1,716)		(53,081)
Other comprehensive income (loss)	70						70
Share-based compensation	9,290			8,449				841
Shares sold at the market	1,990	$ 5,800	$ 1	1,989	$ (4,434)				$ 10,234
Shares sold at the market, shares			117
Issuance of warrants	6,983			6,983
Payment of CEO payroll in shares	114			114
Payment of CEO payroll In shares, shares			11
Exercise of stock options	34			28				6
Exercise of stock options, shares			2
Vesting of nonvested shares, shares			2
Ending balance at Jun. 30, 2024	(220,839)		$ 211	1,830,114			(1,001)	20,472		(2,070,635)	$ 0
Balance, shares at Jun. 30, 2024			21,126								32
Beginning balance at Dec. 31, 2024	(306,424)		$ 236	1,857,662			(1,398)	19,956		(2,182,880)	$ 0
Balance, shares at Dec. 31, 2024			23,635								32
Net loss	(26,370)							(1,104)		(25,266)
Other comprehensive income (loss)	(70)						(70)
Share-based compensation	3,184			2,587				597
Shares sold at the market	6,343		$ 28	6,315
Shares sold at the market, shares			2,783
Issuance of warrants	398			398
Payment of CEO payroll in shares	89		$ 1	88
Payment of CEO payroll In shares, shares			33
Issuance of shares for services	39			39				0
Issuance of shares for services, shares			11
Issuance of shares in connection with debt agreement	220		$ 1	219
Issuance of shares in connection with debt agreement, shares			66
Vesting of nonvested shares, shares			1
Exercise of stock options and employee share purchases	44			43				1
Exercise of stock options and employee share purchases, shares			18
Issuance of shares for employee salaries	149			171		$ (22)
Issuance of shares for employee salaries, shares			24			(8)
Retirement of treasury shares				(22)		$ 22
Retirement of treasury shares, share			(8)			8
Ending balance at Mar. 31, 2025	(322,398)		$ 266	1,867,500			(1,468)	19,450		(2,208,146)	$ 0
Balance, shares at Mar. 31, 2025			26,563								32
Beginning balance at Dec. 31, 2024	(306,424)		$ 236	1,857,662			(1,398)	19,956		(2,182,880)	$ 0
Balance, shares at Dec. 31, 2024			23,635								32
Net loss	(56,382)
Other comprehensive income (loss)	(106)
Share-based compensation								1,497
Ending balance at Jun. 30, 2025	(336,308)		$ 300	1,882,704			(1,504)	18,293		(2,236,101)	$ 0
Balance, shares at Jun. 30, 2025			30,004								32
Beginning balance at Mar. 31, 2025	(322,398)		$ 266	1,867,500			(1,468)	19,450		(2,208,146)	$ 0
Balance, shares at Mar. 31, 2025			26,563								32
Net loss	(30,012)							(2,057)		(27,955)
Other comprehensive income (loss)	(36)						(36)
Share-based compensation	3,338			2,438				900
Shares sold at the market	12,217		$ 31	12,186
Shares sold at the market, shares			3,136
Payment of CEO payroll in shares	114			114
Payment of CEO payroll In shares, shares			40
Issuance of shares for services	26			26
Issuance of shares for services, shares			9
Issuance of shares in connection with debt agreement	404		$ 2	402
Issuance of shares in connection with debt agreement, shares			179
Vesting of nonvested shares, shares			15
Issuance of shares for employee salaries	39		$ 1	103		$ (65)
Issuance of shares for employee salaries, shares			91			(29)
Retirement of treasury shares				(65)		$ 65
Retirement of treasury shares, share			(29)			29
Ending balance at Jun. 30, 2025	$ (336,308)		$ 300	$ 1,882,704			$ (1,504)	$ 18,293		$ (2,236,101)	$ 0
Balance, shares at Jun. 30, 2025			30,004								32

AGENUS INC 10-Q